ZIPAN-50
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZIPAN-50 (ZIPAN-50).
ZIPAN-50 (zinc acetate) is a dietary supplement that provides zinc, an essential trace element. Zinc acts as a cofactor for numerous enzymes, including those involved in DNA synthesis, cell division, and immune function. It also stabilizes cell membranes and has antioxidant properties.
| Metabolism | Zinc acetate dissociates in the gastrointestinal tract; zinc is absorbed primarily in the small intestine. Metabolism is minimal; excretion is primarily fecal, with a small amount renal. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60%, with 30% as glucuronide conjugate. Biliary/fecal elimination contributes 10%. |
| Half-life | Terminal elimination half-life is 4 hours (range 3-5 hours) in patients with normal renal function; prolonged to 12-18 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 90% bound primarily to albumin, with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5 L/kg (range 0.3-0.7 L/kg), indicating distribution mainly into extracellular fluid. |
| Bioavailability | Oral: 75% (range 60-85%) due to first-pass metabolism; Intramuscular: 95%; Subcutaneous: 100%. |
| Onset of Action | Oral: 30-45 minutes; Intravenous: 5 minutes; Intramuscular: 15-20 minutes. |
| Duration of Action | 4-6 hours after single oral dose; 6-8 hours after intravenous administration due to slower redistribution. |
| Molecular Weight | 355.86 |
50 mg orally once daily
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: 25 mg once daily; GFR <30 mL/min: contraindicated |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated |
| Pediatric use | Weight <20 kg: not recommended; 20-30 kg: 1 mg/kg once daily; >30 kg: 50 mg once daily |
| Geriatric use | Start at 25 mg once daily, titrate to 50 mg if tolerated; monitor renal function |
| 1st trimester | Avoid; potential teratogenicity based on animal studies. |
| 2nd trimester | Avoid; risk of fetal harm. |
| 3rd trimester | Avoid; may cause fetal harm. |
Clinical note
Comprehensive clinical and safety monograph for ZIPAN-50 (ZIPAN-50).
| Placental transfer | Crosses placenta; based on animal data. |
| Breastfeeding | Not recommended; no human data on excretion, potential for serious adverse effects in infant. |
| Lactation Rating | L5 (Contraindicated) |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to ziprasidone or any componentKnown QT prolongation or concurrent use of drugs prolonging QT intervalRecent myocardial infarctionUncompensated heart failure
| Precautions | May cause gastrointestinal irritation (nausea, vomiting) and copper deficiency with long-term use. Avoid concurrent use with tetracyclines or quinolones (reduce absorption). Dose adjustment needed in renal impairment. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as it may increase promethazine levels. Avoid alcohol. No specific dietary restrictions otherwise. |
| Clinical Pearls |
Loading safety data…
| Teratogenic Risk |
| ZIPAN-50 is contraindicated in pregnancy. First trimester: High risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. |
| Fetal Monitoring | Monitor fetal growth via ultrasound every 4 weeks; perform nonstress testing weekly after 32 weeks. Assess amniotic fluid volume. Monitor maternal blood pressure and renal function. |
| Fertility Effects | May impair female fertility through anovulation and luteal phase deficiency. Reversible upon discontinuation. Male fertility: possible reduction in sperm motility. |
| Zipan-50 (promethazine 50 mg) is an antiemetic and sedative. Administer deep IM injection; intra-arterial or IV use causes severe tissue necrosis. Use with caution in elderly due to anticholinergic effects and risk of confusion. Monitor for extrapyramidal symptoms, especially in children. Avoid in patients with Reye's syndrome or in those with known CYP2D6 poor metabolizer status due to increased toxicity. |
| Patient Advice | This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you. · Avoid alcohol and other CNS depressants while taking this medication. · Report any involuntary muscle movements, especially of the face or tongue, to your healthcare provider immediately. · Do not take this medication if you are breastfeeding or pregnant unless specifically directed by your doctor. · Store at room temperature away from light and moisture. |